Abstract 2145
Background
The pathological classification of pancreatic neuroendocrine neoplasms (PanNENs) has been revised based on the World Health Organization (WHO) 2017 classification. Well-differentiated PanNENs were previously classified as G1, G2, or G3 according to the Ki-67 labeling index (LI), which shows the cell proliferation ability. Although the Ki67 LI cut-off for G1 and G2 was changed from ≤2% to < 3% from WHO 2010 to 2017, there are few reports on the impact of G2 tumor malignancy associated with this change.
Methods
Patients with PanNENs G1/G2 classified by WHO 2017 Ki-67 LI cut-off who underwent pancreatic resection at our institution between July 1987 and March 2019 were retrospectively analyzed. We excluded patients with synchronous distant metastasis at the time of diagnosis. Their clinicopathological variables were analyzed.
Results
Sixty-two patients (median age: 58 years; range: 18–84 years) were examined. The G1/G2 groups comprised 40/22 and 48/14 patients based on WHO 2010 and 2017 classifications, respectively. Eight patients were reclassified from G2 to G1, two of which were T2 or more based on TNM classification; one patient had lymph node metastasis positivity, and all patients survived without recurrence. Disease recurrence occurred in 4/4 G1/G2 patients according to both WHO 2010 and 2017. G2 patients had shorter 5- and 10-year disease-free survivals (DFSs) than those of G1 patients based on WHO 2010 (90.9% and 90.9% vs. 84.5% and 70.4%, p = 0.179) and significantly shorter DFS based on WHO 2017 (91.9% and 91.9% vs. 78.6% and 58.9%, p = 0.036). The Ki-67 LI cut-off by ROC analysis was 3%, supporting the WHO 2017 classification. In multivariate analysis for DFS, tumor size >25 mm and vascular invasion positivity, but not G2, were risk factors for recurrence. The high-risk group with these factors had significantly worse 5- and 10-year disease-specific survivals (DSSs) compared to the low-risk group (100% and 100% vs. 90.9% and 68.2%, p = 0.045).
Conclusions
Revision of the Ki-67 LI cut-off for PanNENs G1/G2 based on WHO 2017 may be appropriate but G2 is not a risk factor for DFS. Tumor size >25 mm and vascular invasion positivity are potential risk factors. High-risk patients should be closely monitored during follow-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5629 - Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumor infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Presenter: Luca Campedel
Session: Poster Display session 2
Resources:
Abstract
5792 - A novel PET parameter for cancer stem cell metabolism: early prediction of chemosensitivity to neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Chanwoo Kim
Session: Poster Display session 2
Resources:
Abstract
3728 - Using nodal ratio to predict recurrence in patients with 4 or more positive lymph nodes early stage breast cancer
Presenter: Besma Graja
Session: Poster Display session 2
Resources:
Abstract
3395 - Re-sentinel node biopsy for local recurrence after breast-conserving surgery
Presenter: Yuka Matsubara
Session: Poster Display session 2
Resources:
Abstract
4302 - Assessment of prognostic and therapeutic factors in men with breast cancer
Presenter: Daniel Herrero Rivera
Session: Poster Display session 2
Resources:
Abstract
4263 - Genomic Profiling of Chinese Breast Cancer Patients
Presenter: Zhonghua Tao
Session: Poster Display session 2
Resources:
Abstract
2406 - Genome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
Presenter: Naomi Walsh
Session: Poster Display session 2
Resources:
Abstract
2575 - Next-generation DNA Sequencing (NGS) Results for Tumors From Phase 2 ABRAZO Study of Talazoparib After Platinum or Cytotoxic Non-Platinum Regimens in Patients (pts) With Advanced Breast Cancer (ABC) and Germline BRCA1/2 (gBRCA) Mutations
Presenter: Nicholas C. Turner
Session: Poster Display session 2
Resources:
Abstract
4499 - FGFR1 and CCND1 gene amplifications are associated with breast cancer resistance to aromatase inhibitors
Presenter: Evgeny Imyanitov
Session: Poster Display session 2
Resources:
Abstract
4110 - Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe Experience
Presenter: Sercan Aksoy
Session: Poster Display session 2
Resources:
Abstract